EUVIMEDEUVIMED entdecken
Open Access

Salivary α‐Synuclein as a Candidate Biomarker of Parkinsonism in 22q11.2 Deletion Syndrome

Martina Fanella, Emanuele Cerulli Irelli, Tommaso Accinni, Fabio Di Fabio, Carolina Putotto, Federica Pulvirenti, Francesco E Bellomi, Carlo Di Bonaventura iD, Giorgio Vivacqua

Movement Disorders Clinical Practice · 2024

DOI: 10.1002/mdc3.14046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2024. Verfasst von Martina Fanella und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fabrizio Spaziani Hospital, Frosinone, Italy. Hauptthemen laut MEDLINE: alpha-Synuclein, Saliva, Biomarkers, Parkinsonian Disorders. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

22q11.2 deletion syndrome (22q11.2DS) has been linked to an increased risk of early‐onset Parkinson's disease. However, the pathophysiological mechanisms underlying parkinsonism remain poorly understood.

Objective

The objective is to investigate salivary total α‐synuclein levels in 22q11.2DS patients with and without parkinsonian motor signs.

Methods

This cross‐sectional study included 10 patients with 22q11.2DS with parkinsonism (Park+), ten 22q11.2DS patients without parkinsonism (Park−), and 10 age and sex‐comparable healthy subjects (HS). Salivary and serum α‐synuclein levels were measured using enzyme‐linked immunosorbent assay.

Results

Salivary total α‐synuclein concentration was significantly lower in Park (+) patients than in Park (−) patients and HS ( P = 0.007). In addition, salivary α‐synuclein showed good accuracy in discriminating Park (+) from Park (−) patients (area under the curve = 0.86) and correlated with motor severity and cognitive impairment.

Conclusion

This exploratory study suggests that the parkinsonian phenotype of 22q11.2DS is associated with a reduced concentration of monomeric α‐synuclein in biological fluids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinSalivaBiomarkersParkinsonian DisordersDiGeorge SyndromeHumansMaleFemaleCross-Sectional StudiesAdultYoung AdultMiddle AgedAdolescent

Stichwörter der Autor:innen

DiGeorge syndromeParkinson's disease (PD)serumα synuclein (a‐synuclein)

Substanzen

alpha-SynucleinBiomarkers

Autor:innen und Institutionen

  • Fabrizio Spaziani Hospital, Frosinone, Italy.
  • Department of Human Neurosciences, Sapienza University, Rome, Italy.
  • AOU Policlinico Umberto I, Rome, Italy.
  • Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Rome, Italy.
  • Regional Reference Centre for Primary Immune Deficiencies, AOU Policlinico Umberto I, Rome, Italy.
  • Department of Microscopic and Ultrastructural Anatomy - Integrated Research Center (PRAAB) - Campus Biomedico University of Rome, Rome, Italy.

ORCID-Profile: Carlo Di Bonaventura

Zitieren

APA

Fanella, M., Cerulli Irelli, E., Accinni, T., Di Fabio, F., Putotto, C., Pulvirenti, F., Bellomi, F. E., Di Bonaventura, C., & Vivacqua, G. (2024). Salivary α‐Synuclein as a Candidate Biomarker of Parkinsonism in 22q11.2 Deletion Syndrome. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.14046

Vancouver

Fanella M, Cerulli Irelli E, Accinni T, Di Fabio F, Putotto C, Pulvirenti F, et al. Salivary α‐Synuclein as a Candidate Biomarker of Parkinsonism in 22q11.2 Deletion Syndrome. Movement Disorders Clinical Practice. 2024. doi:10.1002/mdc3.14046

BibTeX
@article{Fanella2024,
  author = {Fanella, Martina and Cerulli Irelli, Emanuele and Accinni, Tommaso and Di Fabio, Fabio and Putotto, Carolina and Pulvirenti, Federica and Bellomi, Francesco E and Di Bonaventura, Carlo and Vivacqua, Giorgio},
  title = {Salivary α‐Synuclein as a Candidate Biomarker of Parkinsonism in 22q11.2 Deletion Syndrome},
  journal = {Movement Disorders Clinical Practice},
  year = {2024},
  doi = {10.1002/mdc3.14046}
}
Kostenlos starten →